Keeping Tabs on Polyhistidine Tags | GEN Magazine Articles | GEN

Attitudes toward Affinity Purification Range from a Desire to Move beyond Old Specificity/Yield Trade-Offs to a Willingness to Explore New Polyhistidine Technology Spin-Offs Angelo DePalma, Ph.D.   Affinity tagging, a popular method for capturing or immobilizing proteins, has several incarnations, none more popular than polyhistidine tagging. In polyhistidine tagging, 6 to 10 histidine residues are added recombinantly to either the protein’s C- or N-terminus.   Fewer or more histidines are also possible. After expression, the protein is captured by means of immobilized metal affinity chromatography (IMAC). Subsequently, the protein is eluted in high purity by swamping the column with imidazole,
Read More

Categories: News and Press Releases.

Introducing a New Science Director

Maine Biotechnology Services, Inc. is pleased to announce the addition of Dr. Stephen Pelsue as Science Director. Dr. Pelsue is providing technical expertise and leadership to our scientific team as they work to develop and integrate new tools, technologies, and processes that enhance our ability to address challenging new antibody targets on behalf of our client base. Prior to joining MBS, Dr. Pelsue was an Associate Professor of Immunology & Molecular Biology at the University of Southern Maine, where he ran a research program investigating the development of autoantibodies in autoimmune diseases, particularly focused on Lupus.  In addition to his research program he
Read More

Categories: New Products, News, Press Releases, and Technical Blog.

25th Year at MBS

(PRWEB) June 09, 2015 Maine Biotechnology Services, a premier provider of antibody based services is celebrating its 25th year in business. In 1990, Dr. Joseph Chandler founded MBS with the intent to be true partners to life science researchers in their pursuit of ideal antibodies for any application. Over the course of 25 years, MBS has delivered on that promise, adding broad and deep technical expertise in antibody and assay related technologies. MBS serves customers in a dynamic marketplace where timely assay performance is paramount to pharmaceutical and diagnostic development. Continual investment into tools, protocols, and process development have kept
Read More

Categories: News and Press Releases.

MBS-UNC Partnership Provides Monoclonal Antibodies to Aid in the Diagnosis of Chikungunya Virus

Today, MBS is announcing the release of three monoclonal antibodies to chikungunya virus. All three antibodies detect active strains of chikungunya virus by ELISA Portland, Maine (PRWEB) January 08, 2015 In 2012 Maine Biotechnology Services entered into a partnership with Drs. Mark Heise and Kristin Long of the University of North Carolina Medical School, with the objective of developing monoclonal antibodies to support ongoing research efforts to advance adequate vaccine and rapid detection methods for chikungunya virus (CHIKV), an emerging global infection. Today, MBS is announcing the release of three monoclonal antibodies resulting from that partnership. Inactivated CHIKV was used
Read More

Categories: News and Press Releases.

Complete Panel of Norovirus Antibodies

Maine Biotechnology Services developed a comprehensive panel of antibodies specific for human Norovirus, including GII.4 2012 SYDNEY STRAIN.  There are currently five known genogroups, of which three cause human disease: GI, GII, and GIV.  According to the CDC, since 2002 GII.4 has been the most common cause of Norovirus outbreaks. All MBS Norovirus antibodies have been tested across a broad range of strains, as reported in the table below. MAB227P demonstrated the ability to block ligand binding in surrogate neutralization assays.  MAB228P, developed against GI.1 1968 virus like particles (VLPs), recognizes additional GI types. MAB242P, the most recently developed antibody, is
Read More

Categories: New Products, News, Press Releases, R&D Updates, and Uncategorized.

Recombinant Protein Expression Now Available at Maine Biotechnology Services

Portland Maine – Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding value and efficiency to custom antibody development with MBS. A typical recombinant antigen project at MBS will begin with a careful analysis of the protein sequence and characteristics to assess its suitability for bacterial expression. MBS
Read More

Categories: News and Press Releases.

Anti-HIS tag Antibody from MBS Incorporated into ForteBio Dip and Read Anti-HIS (HIS2) Biosensors

Portland Maine –  MBS MAB230P, monoclonal antibody to the polyhistidine (HIS) tag has been incorporated into the second generation Forte Bio Anti-HIS biosensors for rapid quantitative measurement of HIS tagged proteins.  MAB230P was selected by ForteBio after demonstrating high specificity and excellent sensitivity, detecting HIS tagged proteins in nanogram quantities.  The antibody is broadly reactive, recognizing HIS tags of 4X or greater, engineered at either the N- or C-terminus of the protein. The internal development and production of MAB230P allows MBS to maintain the highest quality standards and the ability to offer the lowest price in the marketplace.  The MAB230P
Read More

Categories: New Products, News, and Press Releases.

MBS-USDA Partnership Provides Monoclonal Antibodies to Aid in the Containment of Rift Valley Fever Virus

Portland, Maine- In July 2012, Maine Biotechnology Services entered into a partnership with Dr. Scott McVey, supervisor of the USDA-Agricultural Research Service  (USDA-ARS) Arthropod Borne Animal Disease Research Unit, with the objective of developing monoclonal antibodies to support ongoing research efforts to advance adequate vaccine and rapid detection methods for Rift Valley Fever Virus in Africa. MBS is announcing the release of the first two antibodies resulting from that partnership; a functioning matched pair demonstrating specificity to the nucleocapsid protein of the virus. These antibodies have applications as detection reagents for circulating antigen, mosquito carriers, or as components of differentiation
Read More

Categories: News and Press Releases.